Nuvalent Inc.

This program provides access to an experimental drug called zidesamtinib for adults with advanced, ROS1-positive cancers, primarily lung cancer. It is for patients who have already tried at least one other targeted therapy and have no other satisfactory treatment options availabl…

This is the first study in people testing a new oral drug called NVL-330 for advanced lung cancer that has a specific genetic change called HER2. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also look for early signs that the dr…

This program provides access to an investigational drug called neladalkib for patients with advanced ALK-positive cancers, including lung cancer. It is for adults who have tried other treatments without success and cannot join a formal clinical trial. The goal is to offer a poten…

This study tests whether a new drug called NVL-655 works better than the current standard treatment (alectinib) for people with advanced ALK-positive lung cancer who haven't had treatment before. About 450 participants will be randomly assigned to receive either the new drug or t…

This study is testing a new oral medication called NVL-655 for people with advanced cancers that have a specific genetic change called ALK. The trial aims to find the safest and most effective dose and see how well the drug shrinks tumors. It's for adults with advanced lung cance…

This clinical trial is testing an experimental drug called zidesamtinib for people with advanced cancers that have a specific genetic change called ROS1. The study aims to find the safest and most effective dose, and then see how well the drug shrinks tumors in patients with ROS1…